for Journals by Title or ISSN
for Articles by Keywords
help
  Subjects -> MEDICAL SCIENCES (Total: 6073 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (175 journals)
    - ANAESTHESIOLOGY (63 journals)
    - CARDIOVASCULAR DISEASES (249 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (20 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (165 journals)
    - DENTISTRY (181 journals)
    - DERMATOLOGY AND VENEREOLOGY (125 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (72 journals)
    - ENDOCRINOLOGY (105 journals)
    - EXPERIMENTAL MEDICINE, LABORATORY TECHNIQUE (65 journals)
    - FORENSIC SCIENCES (24 journals)
    - GASTROENTEROLOGY (135 journals)
    - GERONTOLOGY AND GERIATRICS (100 journals)
    - HEMATOLOGY (124 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (81 journals)
    - MEDICAL GENETICS (61 journals)
    - MEDICAL SCIENCES (1675 journals)
    - NURSES AND NURSING (233 journals)
    - OBSTETRICS AND GYNECOLOGY (147 journals)
    - ONCOLOGY (280 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (100 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (105 journals)
    - OTORHINOLARYNGOLOGY (50 journals)
    - PATHOLOGY (87 journals)
    - PEDIATRICS (196 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (105 journals)
    - PSYCHIATRY AND NEUROLOGY (612 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (153 journals)
    - RESPIRATORY DISEASES (81 journals)
    - RHEUMATOLOGY (53 journals)
    - SPORTS MEDICINE (59 journals)
    - SURGERY (274 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (114 journals)

GASTROENTEROLOGY (135 journals)                  1 2     

Abdominal Imaging     Hybrid Journal   (Followers: 11)
Acta Endoscopica     Hybrid Journal  
Acta Gastroenterologica Latinoamericana     Open Access   (Followers: 2)
Actualités Odonto-Stomatologiques     Open Access   (Followers: 3)
AJP Gastrointestinal and Liver Physiology     Full-text available via subscription   (Followers: 6)
Alimentary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 171)
Alimentary Pharmacology & Therapeutics Symposium Series     Hybrid Journal   (Followers: 4)
American Journal of Gastroenterology Supplements     Full-text available via subscription   (Followers: 5)
American Journal of Gastroenterology, The     Hybrid Journal   (Followers: 157)
Arab Journal of Gastroenterology     Full-text available via subscription   (Followers: 3)
Arquivos de Gastroenterologia     Open Access   (Followers: 1)
Australian and New Zealand Continence Journal     Full-text available via subscription   (Followers: 2)
Avances en Odontoestomatologia     Open Access  
Best Practice & Research Clinical Gastroenterology     Full-text available via subscription   (Followers: 4)
BMC Gastroenterology     Open Access   (Followers: 9)
Canadian Journal of Gastroenterology & Hepatology     Hybrid Journal   (Followers: 2)
Case Reports in Gastroenterology     Open Access   (Followers: 4)
Case Reports in Gastrointestinal Medicine     Open Access   (Followers: 3)
Case Reports in Hepatology     Open Access  
Clinical and Experimental Gastroenterology     Open Access   (Followers: 3)
Clinical and Molecular Hepatology     Open Access   (Followers: 1)
Clinical and Translational Gastroenterology     Open Access   (Followers: 2)
Clinical Diabetes     Full-text available via subscription   (Followers: 17)
Clinical Gastroenterology and Hepatology     Hybrid Journal   (Followers: 14)
Clinical Journal of Gastroenterology     Hybrid Journal   (Followers: 8)
Clinical Medicine Insights : Gastroenterology     Open Access   (Followers: 4)
Clinics and Research in Hepatology and Gastroenterology     Hybrid Journal   (Followers: 2)
Clinics in Liver Disease     Full-text available via subscription   (Followers: 3)
Colon & Rectum     Hybrid Journal   (Followers: 3)
coloproctology     Hybrid Journal  
Colorectal Disease     Hybrid Journal   (Followers: 8)
Comparative Hepatology     Open Access   (Followers: 2)
Current Colorectal Cancer Reports     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 15)
Current Gastroenterology Reports     Hybrid Journal   (Followers: 2)
Current Hepatitis Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Gastroenterology     Hybrid Journal   (Followers: 8)
Current Treatment Options in Gastroenterology     Hybrid Journal   (Followers: 4)
Der Gastroenterologe     Hybrid Journal  
Diabetes     Full-text available via subscription   (Followers: 293)
Diabetes Spectrum     Full-text available via subscription   (Followers: 8)
Diagnostic and Therapeutic Endoscopy     Open Access  
Digestion     Full-text available via subscription   (Followers: 6)
Digestive and Liver Disease     Hybrid Journal   (Followers: 8)
Digestive and Liver Disease Supplements     Full-text available via subscription   (Followers: 4)
Digestive Diseases     Full-text available via subscription   (Followers: 157)
Digestive Diseases and Sciences     Hybrid Journal   (Followers: 4)
Digestive Endoscopy     Hybrid Journal   (Followers: 4)
Diseases of the Colon & Rectum     Full-text available via subscription   (Followers: 5)
Diseases of the Esophagus     Hybrid Journal   (Followers: 1)
Dysphagia     Hybrid Journal   (Followers: 161)
Endoscopy     Hybrid Journal   (Followers: 1)
Endoscopy International Open     Open Access  
Endoskopie heute     Hybrid Journal  
Esophagus     Hybrid Journal  
European Journal of Gastroenterology & Hepatology     Hybrid Journal   (Followers: 8)
Evidence-Based Gastroenterology     Full-text available via subscription   (Followers: 3)
Expert Review of Gastroenterology and Hepatology     Full-text available via subscription   (Followers: 3)
Frontline Gastroenterology     Full-text available via subscription   (Followers: 2)
Gastric Cancer     Hybrid Journal  
Gastroenterología y Hepatología     Full-text available via subscription  
Gastroenterología y Hepatología Continuada     Full-text available via subscription  
Gastroenterologie up2date     Hybrid Journal  
Gastroenterology     Hybrid Journal   (Followers: 159)
Gastroenterology and Hepatology from bed to bench     Open Access   (Followers: 3)
Gastroenterology Clinics of North America     Full-text available via subscription   (Followers: 3)
Gastroenterology Insights     Open Access   (Followers: 2)
Gastroenterology Report     Open Access   (Followers: 1)
Gastroenterology Research     Open Access   (Followers: 3)
Gastroenterology Research and Practice     Open Access   (Followers: 4)
Gastrointestinal Cancer : Targets and Therapy     Open Access   (Followers: 2)
Gastrointestinal Endoscopy     Hybrid Journal   (Followers: 8)
Gastrointestinal Endoscopy Clinics of North America     Full-text available via subscription   (Followers: 4)
Gut     Full-text available via subscription   (Followers: 227)
Gut Microbes     Full-text available via subscription   (Followers: 1)
Gut Pathogens     Full-text available via subscription  
Hepatic Medicine: Evidence and Research     Open Access   (Followers: 3)
Hepatitis B Annual     Open Access   (Followers: 2)
Hepatitis Monthly     Open Access  
Hepatitis Research and Treatment     Open Access   (Followers: 4)
Hepatology     Hybrid Journal   (Followers: 15)
Hepatology International     Hybrid Journal   (Followers: 3)
Hepatology Research     Hybrid Journal   (Followers: 6)
HPB: The official journal of the International Hepato Pancreato Biliary Association     Hybrid Journal   (Followers: 3)
Immuno-Gastroenterology     Full-text available via subscription  
Indian Journal of Gastroenterology     Open Access   (Followers: 1)
Inflammatory Bowel Diseases     Hybrid Journal   (Followers: 165)
International Journal of Colorectal Disease     Hybrid Journal  
International Journal of Hepatology     Open Access   (Followers: 2)
International Journal of Stomatological Research     Open Access  
ISRN Gastroenterology     Open Access   (Followers: 2)
Journal Africain d'Hépato-Gastroentérologie     Hybrid Journal   (Followers: 2)
Journal of Clinical Gastroenterology     Hybrid Journal   (Followers: 5)
Journal of Coloproctology     Open Access   (Followers: 1)
Journal of Crohn's and Colitis     Full-text available via subscription   (Followers: 7)
Journal of Crohn's and Colitis Supplements     Full-text available via subscription   (Followers: 1)
Journal of Diabetes Research and Clinical Metabolism     Open Access  
Journal of Digestive Diseases     Hybrid Journal   (Followers: 4)
Journal of Digestive Endoscopy     Open Access   (Followers: 1)
Journal of Gastroenterology     Hybrid Journal   (Followers: 9)

        1 2     

Journal Cover Gastroenterology Clinics of North America
   Journal TOC RSS feeds Export to Zotero [5 followers]  Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 0889-8553
     Published by Elsevier Homepage  [2563 journals]   [SJR: 0.988]   [H-I: 56]
  • Contributors
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3




      PubDate: 2014-08-12T16:29:30Z
       
  • Contents
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3




      PubDate: 2014-08-12T16:29:30Z
       
  • Forthcoming Issues
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3




      PubDate: 2014-08-12T16:29:30Z
       
  • Biologics of IBD
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3
      Author(s): Gary W. Falk



      PubDate: 2014-08-12T16:29:30Z
       
  • Biologic Therapy in Inflammatory Bowel Disease
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3
      Author(s): Edward V. Loftus Jr



      PubDate: 2014-08-12T16:29:30Z
       
  • Immunology of Inflammatory Bowel Disease and Molecular Targets for
           Biologics
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3
      Author(s): Maneesh Dave , Konstantinos A. Papadakis , William A. Faubion Jr.

      Teaser Inflammatory bowel disease (IBD) is an immune-mediated disease and involves a complex interplay of host genetics and environmental influences. Recent advances in the field, including data from genome-wide association studies and microbiome analysis, have started to unravel the complex interaction between host genetics and environmental influences in the pathogenesis of IBD. A drawback of current clinical trials is inadequate or lack of immune phenotyping of patients. However, recent advances in high-throughput technologies provide an opportunity to monitor the dynamic and complex immune system, which may to lead to a more personalized treatment approach in IBD.

      PubDate: 2014-08-12T16:29:30Z
       
  • Index
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3




      PubDate: 2014-08-12T16:29:30Z
       
  • An Update on Anti-TNF Agents in Ulcerative Colitis
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3
      Author(s): Mark A. Samaan , Preet Bagi , Niels Vande Casteele , Geert R. D’Haens , Barrett G. Levesque

      Teaser Anti-tumor necrosis factor-α agents are key therapeutic options for the treatment of ulcerative colitis. Their efficacy and safety have been shown in large randomized controlled trials. The key evidence gained from these trials of infliximab, adalimumab, and golimumab is reviewed along with their effect on mucosal healing and long-term outcomes. Also reviewed are methods for optimizing their effectiveness, including therapeutic drug monitoring and treat-to-target strategies. Finally, remaining unresolved questions regarding their role and effectiveness are considered including how these may be addressed in future clinical trials.

      PubDate: 2014-08-12T16:29:30Z
       
  • Update on Ustekinumab for the Treatment of Crohn's Disease
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3
      Author(s): Yvette Leung , Remo Panaccione

      Teaser Despite the success of antitumor necrosis factor (TNF) therapy in Crohn's disease, there remains a need for biologic therapy that targets other immune pathways of disease. Ustekinumab is a fully human monoclonal immunoglobulin antibody that targets the interleukin (IL)-12 and IL-23 shared P40 subunit. It has been studied in 2 phase 2 randomized, double-blind, placebo-controlled trials in Crohn's disease. This article reviews the clinical efficacy and safety data of ustekinumab in Crohn's disease in anticipation of the final results of the phase III development program in moderate to severe Crohn's disease.

      PubDate: 2014-08-12T16:29:30Z
       
  • Who Should Receive Biologic Therapy for IBD' The Rationale for the
           Application of a Personalized Approach
    • Abstract: Publication date: September 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 3
      Author(s): Jennifer Jones , Juan Nicolás Peña-Sánchez

      Teaser The therapeutic approach in inflammatory bowel disease has evolved to target end-organ inflammation to heal intestinal mucosa and avoid structural damage. Objective therapeutic monitoring is required to achieve this goal. Earlier intervention with biologic therapy has been shown, indirectly, to be associated with higher clinical response and remission rates. A personalized approach to risk stratification with consideration of key clinical factors and inflammatory biomarker concentrations is recommended when deciding whether or not to start a patient on biologic therapy.

      PubDate: 2014-08-12T16:29:30Z
       
  • Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and
           Malignancy)
    • Abstract: Publication date: Available online 5 July 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Joseph D. Feuerstein , Adam S. Cheifetz

      Teaser Anti-tumor necrosis factor-α (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration–approved for moderate to severe IBD: infliximab, adalimumab, golimumab, and certolizumab pegol. For most noninfectious, nonmalignant adverse events, cessation of anti-TNF therapy typically leads to improvement or resolution of drug-induced complications. In this article, the current knowledge regarding the noninfectious and nonmalignant toxicities associated with anti-TNF agents is summarized.

      PubDate: 2014-07-26T04:25:36Z
       
  • The Risk of Malignancy Associated with the Use of Biological Agents in
           Patients with Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 13 June 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Parambir S. Dulai , Corey A. Siegel

      Teaser In this review, the available data regarding the risk of lymphoma, skin cancers, and other malignancies associated with biological agents that are approved and those under investigation for use in inflammatory bowel disease (IBD) are highlighted. How providers may approach the use of these agents in various clinical scenarios is discussed. This review may help providers better understand the true risk of malignancy associated with these agents, thereby leading to an enhanced communication process with patients with IBD when therapeutic decisions are being made.

      PubDate: 2014-07-26T04:25:36Z
       
  • Anti–Tumor Necrosis Factor-α Monotherapy Versus Combination
           Therapy with an Immunomodulator in IBD
    • Abstract: Publication date: Available online 16 June 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Parambir S. Dulai , Corey A. Siegel , Laurent Peyrin-Biroulet

      Teaser Inflammatory bowel disease (IBD) treatment has progressed significantly over the past decade with the advent of biologics. Anti-tumor necrosis factor (anti-TNF) agents are the most widely available biologics, but the optimal approach when using them remains unclear. In this review, we highlight the currently available evidence regarding the use of anti-TNF monotherapy versus combination therapy with an immunomodulator. We focus on those patients at greatest risk for adverse events and outline the clinical approach when considering the use of combination therapy. We review the available tools through which providers may efficiently communicate these data to patients in the clinical setting.

      PubDate: 2014-07-26T04:25:36Z
       
  • Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring
    • Abstract: Publication date: Available online 24 June 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Kirk Lin , Uma Mahadevan

      Teaser Biologic therapies, including the anti–tumor necrosis factor-α and cell adhesion molecule inhibitor drugs, have revolutionized the treatment of moderate-to-severe inflammatory bowel disease. Since the introduction of anti–tumor necrosis factor therapies, the strategy of empiric dose-escalation, either increasing the dose or frequency of administration, has been used to recapture clinical response in inflammatory bowel disease. Disparate clinical outcomes have been linked to serum drug and antidrug antibody levels. Therapeutic drug monitoring has emerged as a framework for understanding and responding to the variability in clinical response and remission.

      PubDate: 2014-07-26T04:25:36Z
       
  • Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease
    • Abstract: Publication date: Available online 24 June 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Siddharth Singh , Darrell S. Pardi

      Teaser Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

      PubDate: 2014-07-26T04:25:36Z
       
  • Update on Janus Kinase Antagonists in Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 24 June 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Brigid S. Boland , William J. Sandborn , John T. Chang

      Teaser Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.

      PubDate: 2014-07-26T04:25:36Z
       
  • Risk of Infections with Biological Agents
    • Abstract: Publication date: Available online 16 June 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Uri Kopylov , Waqqas Afif

      Teaser An increasing proportion of patients with inflammatory bowel disease (IBD) are treated with biological medications. The risk of infectious complications remains a significant concern in patients treated with biologics. Treatment with biological agents in IBD is generally safe, but there may be an increased risk of certain opportunistic infections. Some of the infectious risks are class specific, whereas others are a common concern for all biologics. A careful screening, surveillance, and immunization program, in accordance with available guidelines, is important to minimize any risk of infectious complications.

      PubDate: 2014-07-26T04:25:36Z
       
  • Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel
           Diseases
    • Abstract: Publication date: Available online 25 June 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Masayuki Saruta , Konstantinos A. Papadakis

      Teaser Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including integrins and chemokine receptors, have been successfully targeted for the treatment of IBD. These agents have shown great promise for the induction and maintenance of remission for both Crohn disease and ulcerative colitis. This article discusses currently approved prototypic agents for the treatment of IBD (natalizumab, anti-α4 integrin; vedolizumab, anti-α4β7 integrin), and several other agents in the same class currently under development.

      PubDate: 2014-07-26T04:25:36Z
       
  • The Use of Biologic Agents in Pregnancy and Breastfeeding
    • Abstract: Publication date: Available online 5 July 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Sara Horst , Sunanda Kane

      Teaser Biologic therapies, including anti–tumor necrosis factor antibody therapy and anti-integrin antibodies, are currently approved for the treatment of and are increasingly being used in patients with moderate to severe inflammatory bowel disease, including Crohn disease and ulcerative colitis. Because patients who require these medications are often in their child-bearing years, knowledge of the safety of these medications before and after pregnancy is imperative. This article summarizes the available data regarding the use of biologic therapy during and after pregnancy, highlighting such issues as safety for mother and newborn, length of medication use during pregnancy, and breastfeeding after pregnancy while on biologic therapy.

      PubDate: 2014-07-26T04:25:36Z
       
  • Eosinophilic Gastroenteritis and Related Eosinophilic Disorders
    • Abstract: Publication date: June 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 2
      Author(s): Calman Prussin

      Teaser Eosinophilic gastroenteritis (EGE) represents one member within the spectrum of diseases collectively referred to as eosinophilic gastrointestinal disorders, which includes eosinophilic esophagitis (EoE), gastritis, enteritis, and colitis. EGE is less common than EoE and involves a different site of disease but otherwise shares many common features with EoE. The clinical manifestations of EGE are protean and can vary from nausea and vomiting to protein-losing enteropathy or even bowel obstruction requiring surgery. Although systemic corticosteroids are an effective treatment for EGE, their use results in substantial corticosteroid toxicity. Accordingly, there is a great need for improved therapies for these patients.

      PubDate: 2014-05-10T06:30:12Z
       
  • Index
    • Abstract: Publication date: June 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 2




      PubDate: 2014-05-10T06:30:12Z
       
  • Contents
    • Abstract: Publication date: June 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 2




      PubDate: 2014-05-10T06:30:12Z
       
  • Forthcoming Issues
    • Abstract: Publication date: June 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 2




      PubDate: 2014-05-10T06:30:12Z
       
  • Eosinophilic Esophagitis Clinical Presentation in Children
    • Abstract: Publication date: June 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 2
      Author(s): Chris A. Liacouras , Jonathan Spergel , Laura M. Gober

      Teaser Eosinophilic esophagitis (EoE) is increasing in western nations. Symptoms in infants and young children include feeding difficulties, failure to thrive, and gastroesophageal reflux. School-aged children may present with vomiting, abdominal pain, and regurgitation; adolescents and adults with dysphagia and food impaction. Delayed diagnosis increases risk of stricture formation. Children with untreated EoE have tissue changes resembling airway remodeling. Endoscopy does not always correlate. Management centers on food elimination. Approaches include skin prick and patch testing, removal of foods, or an amino acid formula diet. Long-term elimination diets can produce nutritional deficiencies and have poor adherence.

      PubDate: 2014-05-10T06:30:12Z
       
  • Contributors
    • Abstract: Publication date: June 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 2




      PubDate: 2014-05-10T06:30:12Z
       
  • Clinical Implications and Pathogenesis of Esophageal Remodeling in
           Eosinophilic Esophagitis
    • Abstract: Publication date: Available online 16 April 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Ikuo Hirano , Seema S. Aceves

      Teaser In eosinophilic esophagitis (EoE), remodeling changes are manifest histologically in the epithelium and subepithelium where lamina propria fibrosis, expansion of the muscularis propria, and increased vascularity occur. The clinical symptoms and complications of EoE are largely consequences of esophageal remodeling. Available therapies have demonstrated variable ability to reverse existing remodeling changes of the esophagus. Systemic therapies have the potential of addressing subepithelial remodeling. Esophageal dilation remains a useful, adjunctive therapeutic maneuver in symptomatic adults with esophageal stricture. As novel treatments emerge, it is essential that therapeutic end points account for the fundamental contributions of esophageal remodeling to overall disease activity.

      PubDate: 2014-04-20T11:15:26Z
       
  • Eosinophilic Esophagitis
    • Abstract: Publication date: Available online 13 April 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Ikuo Hirano



      PubDate: 2014-04-15T16:24:05Z
       
  • Eosinophilic Esophagitis
    • Abstract: Publication date: Available online 5 April 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Gary W. Falk



      PubDate: 2014-04-10T16:17:07Z
       
  • Clinical Presentation of Eosinophilic Esophagitis in Adults
    • Abstract: Publication date: Available online 1 April 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Gary W. Falk

      Teaser Eosinophilic esophagitis (EoE) is an increasingly recognized immune antigen-mediated esophageal disease found in both children and adults. It is defined as a clinicopathologic disease characterized by symptoms of esophageal dysfunction accompanied by an eosinophil-predominant esophageal inflammation that occurs in the absence of other causes of esophageal eosinophilia. Classic symptoms in adults include dysphagia to solids and food bolus impaction but a variety of other symptoms are also encountered. Despite the increasing awareness of EoE among practicing physicians, a long delay from onset of symptoms to diagnosis remains a problem in this disease.

      PubDate: 2014-04-05T11:18:53Z
       
  • Steroids in Pediatric Eosinophilic Esophagitis
    • Abstract: Publication date: Available online 29 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Emily M. Contreras , Sandeep K. Gupta

      Teaser Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids. New studies on alternative delivery systems and different corticosteroids (eg, ciclesonide) are encouraging. As knowledge of corticosteroids in eosinophilic esophagitis expands, newer questions continue to arise concerning dose, delivery, and choice of corticosteroids; long-term adverse effects; and maintenance therapies.

      PubDate: 2014-03-31T11:16:13Z
       
  • Dietary Treatment of Eosinophilic Esophagitis
    • Abstract: Publication date: Available online 21 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Nirmala Gonsalves , Amir F. Kagalwalla

      Teaser Emerging evidence supports impaired epithelial barrier function as the key initial event in the development of eosinophilic esophagitis (EoE) and other allergic diseases. Symptom resolution, histologic remission, and prevention of both disease and treatment-related complications are the goals of treatment. Successful dietary treatments include elemental, empirical elimination and allergy test directed diets. Dietary therapy with exclusive elemental diet offers the best response. Cow's milk, wheat, egg, soy, peanut/tree nut, and fish/shellfish are the 6 food antigens most likely to induce esophageal inflammation.

      PubDate: 2014-03-26T12:16:13Z
       
  • Allergic Mechanisms in Eosinophilic Esophagitis
    • Abstract: Publication date: Available online 22 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Joshua B. Wechsler , Paul J. Bryce

      Teaser Eosinophilic esophagitis is rapidly increasing in incidence. It is associated with food antigen–triggered, eosinophil-predominant inflammation, and the pathogenic mechanisms have many similarities to other chronic atopic diseases. Studies in animal models and from patients have suggested that allergic sensitization leads to food-specific IgE and T-helper lymphocyte type 2 cells, both of which seem to contribute to the pathogenesis along with basophils, mast cells, and antigen-presenting cells. In this review our current understandings of the allergic mechanisms that drive eosinophilic esophagitis are outlined, drawing from clinical and translational studies in humans as well as experimental animal models.

      PubDate: 2014-03-26T12:16:13Z
       
  • Eosinophilic Esophagitis Overview of Clinical Management
    • Abstract: Publication date: Available online 21 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Alain M. Schoepfer , Ikuo Hirano , David A. Katzka

      Teaser A validated disease-specific symptom-assessment tool for eosinophilic esophagitis (EoE) has yet to be approved by regulatory authorities for use in clinical trials. Relevant end points for daily practice include EoE-related symptoms and esophageal eosinophilic inflammation. Endoscopic features should also be taken into account when establishing a therapy plan. A reasonable clinical goal is to achieve a reduction in EoE-related symptoms and esophageal eosinophilic inflammation. Evidence is increasing to support an anti-inflammatory maintenance therapy, as this can reduce esophageal remodeling. In EoE patients in clinical remission, annual disease monitoring with symptom, endoscopic, and histologic assessments of sustained treatment response is recommended.

      PubDate: 2014-03-26T12:16:13Z
       
  • Eosinophilic Esophagitis Interactions with Gastroesophageal Reflux Disease
    • Abstract: Publication date: Available online 24 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Edaire Cheng , Rhonda F. Souza , Stuart Jon Spechler

      Teaser Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis (EoE) are not mutually exclusive. The notion that GERD and EoE can be distinguished by the response to proton pump inhibitor (PPI) treatment is based on the mistaken assumption that gastric acid suppression is the only important therapeutic effect of PPIs, and therefore only GERD can respond to PPIs. We believe that a clinical or histologic response to PPIs does not rule in GERD or rule out EoE. We recommend a trial of PPI therapy for patients with symptomatic esophageal eosinophilia, even if the diagnosis of EoE seems clear-cut.

      PubDate: 2014-03-26T12:16:13Z
       
  • Genetic and Epigenetic Underpinnings of Eosinophilic Esophagitis
    • Abstract: Publication date: Available online 24 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Joseph D. Sherrill , Marc E. Rothenberg

      Teaser Eosinophilic esophagitis (EoE) is a complex, polygenic disorder caused by genetic predisposition and environmental exposures. Because of the recent emergence of EoE as a bona fide global health concern, a paucity of available therapeutic and diagnostic options exists. However, rapid progress has been made in an effort to rectify this lack and to improve understanding of the factors that cause EoE. This article highlights key advances in elucidating the genetic (and epigenetic) components involved in EoE.

      PubDate: 2014-03-26T12:16:13Z
       
  • Eosinophilic Esophagitis Historical Perspective on an Evolving Disease
    • Abstract: Publication date: Available online 24 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Stephen E. Attwood , Glenn T. Furuta

      Teaser Initial case series describing children and adults with symptoms related to esophageal dysfunction and dense esophageal eosinophilia lead to recognition of a “new” disease, eosinophilic esophagitis (EoE). Clinical, basic, and translational studies have provided a deeper understanding of this somewhat enigmatic disease that mechanistically is defined as an antigen-driven condition limited to the esophagus. This article summarizes many of the key historical features of EoE and provides a glimpse of potential future developments.

      PubDate: 2014-03-26T12:16:13Z
       
  • Steroid Treatment of Eosinophilic Esophagitis in Adults
    • Abstract: Publication date: Available online 24 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Jeffrey A. Alexander

      Teaser Topical steroid therapy has been used to treat eosinophilic esophagitis (EoE) for more than 15 years. We review the treatment trials of topical steroid therapy in adult patients with EoE. Currently, there is no commercially available preparation designed to deliver the steroid to the esophagus. Current regimens consist of swallowing steroid preparations designed for inhalation treatment for asthma. In the short term, steroids are associated with an approximately 15% to 25% incidence of asymptomatic esophageal candidiasis, but otherwise appear to be well tolerated.

      PubDate: 2014-03-26T12:16:13Z
       
  • Histopathologic Features of Eosinophilic Esophagitis and Eosinophilic
           Gastrointestinal Diseases
    • Abstract: Publication date: Available online 19 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Margaret H. Collins

      Teaser Eosinophilic esophagitis (EoE) shows characteristic microscopic pathologic features in endoscopically obtained esophageal biopsies, including an eosinophil-rich inflammatory infiltrate in esophageal epithelium, but other inflammatory cells are also increased. Additional alterations are found in epithelium and lamina propria. Esophageal biopsy pathology is a sensitive but not specific marker for EoE related to antigen exposure. Several of the pathologic features of EoE correlate with dysregulated genes in the EoE transcriptome. Eosinophilic gastrointestinal diseases affecting the remainder of the gastrointestinal tract are less well characterized; this article discusses pathologic features in mucosal biopsies that could form the basis for diagnosis and future study.

      PubDate: 2014-03-21T12:16:16Z
       
  • Epidemiology of Eosinophilic Esophagitis
    • Abstract: Publication date: Available online 19 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Evan S. Dellon

      Teaser In this article, the epidemiology of eosinophilic esophagitis (EoE) is reviewed. Demographic features and natural history are described, the prevalence and incidence of EoE are highlighted, and risk factors for EoE are discussed. EoE can occur at any age, there is a male predominance, it is more common in whites, and there is a strong association with atopic diseases. EoE is chronic, relapses are frequent, and persistent inflammation increases the risk of fibrostenotic complications. The prevalence is currently estimated at 0.5–1 in 1000, and EoE is now the most common cause of food impaction. The incidence of EoE is approximately 1/10,000 new cases per year, and the increase in incidence is outpacing increases in recognition and endoscopy volume, but the reasons for this evolving epidemiology are not yet fully delineated.

      PubDate: 2014-03-21T12:16:16Z
       
  • Eosinophilic Esophagitis Emerging Therapies and Future Perspectives
    • Abstract: Publication date: Available online 14 March 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Alex Straumann

      Teaser Twenty years have passed since eosinophilic esophagitis was first recognized as a new and distinct entity. Current treatment modalities for eosinophilic esophagitis include the “3 Ds”: drugs, allergen avoidance with diet, and esophageal dilation. Drugs entail the limitation that only corticosteroids have a proven efficacy; most other compounds evoke only a minimal effect. Diets must be maintained continuously and they interfere markedly with the quality of life, possibly even involving some risk of malnutrition. A greater understanding of the immunopathogenesis, natural history, and disease spectrum will inevitably lead to improved therapeutic outcomes for this emerging entity.

      PubDate: 2014-03-16T12:16:27Z
       
  • Contributors
    • Abstract: Publication date: March 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 1




      PubDate: 2014-02-05T07:19:24Z
       
  • Contents
    • Abstract: Publication date: March 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 1




      PubDate: 2014-02-05T07:19:24Z
       
  • Forthcoming Issues
    • Abstract: Publication date: March 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 1




      PubDate: 2014-02-05T07:19:24Z
       
  • Gastroesophageal Reflux Disease
    • Abstract: Publication date: March 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 1
      Author(s): Gary W. Falk



      PubDate: 2014-02-05T07:19:24Z
       
  • Role of Endoscopy in GERD
    • Abstract: Publication date: March 2014
      Source:Gastroenterology Clinics of North America, Volume 43, Issue 1
      Author(s): Virender K. Sharma

      Teaser Endoscopy is commonly performed for the diagnosis and management of gastroesophageal reflux disease (GERD). Endoscopy allows the physician to evaluate esophageal mucosa for evidence of esophagitis and Barrett esophagus, to obtain mucosal biopsies for evaluation of such conditions as eosinophilic esophagitis and diagnosis and grading of Barrett esophagus, and to apply various therapies. In a patient with suboptimal response to GERD therapy, endoscopy excludes other etiologies as a cause of patients’ symptoms. Newer endoscopic therapies for GERD are available or are in development. Advances in imaging techniques in development will improve the diagnostic yield of endoscopy and may replace the need for mucosal biopsies.

      PubDate: 2014-02-05T07:19:24Z
       
  • Barium Esophagram Does It Have a Role in Gastroesophageal Reflux
           Disease'
    • Abstract: Publication date: Available online 7 January 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Mark E. Baker , David M. Einstein

      Teaser The barium esophagram is an integral part of the assessment and management of patients with gastroesophageal reflux disease (GERD) before, and especially after, antireflux procedures. While many of the findings on the examination can be identified with endosocopy, a gastric emptying study and an esophageal motility examination, the barium esophagram is better at demonstrating the anatomic findings after anti-reflux surgery, especially in symptomatic patients. These complementary examinations, when taken as a whole, fully evaluate a patient with suspected GERD as well as symptomatic patients after antireflux procedures.

      PubDate: 2014-01-07T22:17:51Z
       
  • What's New in Gastroesophageal Reflux Disease for 2014
    • Abstract: Publication date: Available online 7 January 2014
      Source:Gastroenterology Clinics of North America
      Author(s): Joel E. Richter



      PubDate: 2014-01-07T22:17:51Z
       
  • Pathophysiology of Gastroesophageal Reflux Disease
    • Abstract: Publication date: Available online 27 December 2013
      Source:Gastroenterology Clinics of North America
      Author(s): Guy E. Boeckxstaens , Wout O. Rohof

      Teaser Gastroesophageal reflux disease (GERD) is one of the most common digestive diseases in the Western world, with typical symptoms, such as heartburn, regurgitation, or retrosternal pain, reported by 15% to 20% of the general population. The pathophysiology of GERD is multifactorial. Our understanding of these factors has significantly improved in recent years, with increased understanding of the acid pocket and hiatal hernia and how these factors interact. Although our insight has significantly increased over the past years, more studies are required to better understand symptom generation in GERD, especially in patients with therapy-resistant symptoms.

      PubDate: 2013-12-28T22:28:35Z
       
  • Symptom Predictability in Gastroesophageal Reflux Disease and Role of
           Proton Pump Inhibitor Test
    • Abstract: Publication date: Available online 27 December 2013
      Source:Gastroenterology Clinics of North America
      Author(s): David S. Estores

      Teaser There are problems with the definition, assessment, and measurement of gastroesophageal reflux disease (GERD). The Reflux Disease Questionnaire and the GERD questionnaire are patient-reported outcome (PRO) measures for use in a primary care setting, which are easy to use and are validated. There is no widely accepted definition of a proton pump inhibitor test and performance of the test in the clinical setting is not standardized. The use of the PRO measures in primary care with predetermined cutoff values may help to reduce the cost of diagnosing GERD and increasing rates of response for evaluated patients to acid suppression.

      PubDate: 2013-12-28T22:28:35Z
       
  • Epidemiology of Gastroesophageal Reflux Disease
    • Abstract: Publication date: Available online 27 December 2013
      Source:Gastroenterology Clinics of North America
      Author(s): Joel H. Rubenstein , Joan W. Chen

      Teaser The prevalence of gastroesophageal reflux disease (GERD) symptoms increased approximately 50% until the mid-1990s, when it plateaued. The incidence of complications related to GERD including hospitalization, esophageal strictures, esophageal adenocarcinoma, and mortality also increased during that time period, but the increase in esophageal adenocarcinoma has since slowed, and the incidence of strictures has decreased since the mid-1990s. GERD is responsible for the greatest direct costs in the United States of any gastrointestinal disease, and most of those expenditures are for pharmacotherapy. Risk factors for GERD include obesity, poor diet, lack of physical activity, consumption of tobacco and alcohol, and respiratory diseases.

      PubDate: 2013-12-28T22:28:35Z
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014